Clinical Trial Update: A Comparison of Esmolol and Remifentanil to Reduce Blood Loss [Phase 4]

View source ↗

Summary

This clinical trial update reports on a Phase 4 study comparing esmolol and remifentanil to reduce blood loss in patients with a deviated nasal septum.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deviated Nasal Septum

Drugs mentioned

• Brevibloc (esmolol)
• Ultiva (remifentanil)

Snippet

Sponsor: Diskapi Teaching and Research Hospital | Conditions: Deviation Septum Nasal | Phase 4 | Status: UNKNOWN